Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Albireo Pharma, Inc. (ALBO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
24.98-0.86 (-3.33%)
At close: 4:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close25.84
Open25.89
Bid24.50 x 800
Ask26.35 x 1000
Day's Range24.77 - 26.18
52 Week Range23.51 - 43.41
Volume204,763
Avg. Volume148,387
Market Cap479.484M
Beta (5Y Monthly)1.51
PE Ratio (TTM)N/A
EPS (TTM)-6.96
Earnings DateMay 06, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est75.57
  • TipRanks

    The Recent Pullback in These 2 Stocks Is a Buying Opportunity, Say Analysts

    While markets are on the way up – the S&P 500 is just above 4,700, a record high – some individual stocks have seen their share prices fall. This is not always a poor reflection on the stock; perfectly sound companies can see their share price drop, without indicating a collapse or poor worth. So, when fundamentally sound stocks plunge, that can spell opportunity for investors. And Wall Street’s analysts have been busy finding those stocks. With this in mind, we scoured the TipRanks database and

  • GlobeNewswire

    Albireo Announces New Phase 3 Data for Bylvay™ (odevixibat) in PFIC and First Reveal of New Next Generation Bile Acid Modulator Data at AASLD The Liver Meeting® 2021

    – Evidence of long-term clinical treatment benefit of Bylvay™ (odevixibat) showing improved liver health and function across PFIC types – – Data show Bylvay therapy up to 128 weeks, sustained improvements in hepatic health, quality of sleep and growth, reducing disease burden – – First data on A2342, the first oral systemic NTCP inhibitor, shows inhibition of Hepatitis B viral entry and replication in preclinical models – – Company to host post-AASLD call on November 16, 2021 at 10 a.m. ET – BOS

  • GlobeNewswire

    Albireo to Present at Upcoming Investor Conferences

    BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, Simon Harford, Chief Financial Officer and other members of the Company’s management team will be presenting at the following investor conferences: Jefferies London Healthcare ConferenceWednesday, November 17 at 11:20 a.m. GMT / 6:20 a.m. ET Piper Sandler 33rd Annual Virtual Healt

Advertisement
Advertisement